Latest Polycomb-group proteins Stories
Finding caps three years of research led by biochemists at NYU Langone Medical Center NEW YORK, Dec.
A single embryonic stem cell can develop into more than 200 specialized cell types that make up our body.
The first detailed and complete picture of a protein complex that is tied to human birth defects as well as the progression of many forms of cancer has been obtained by an international team of researchers led by scientists with the U.S. Department of Energy (DOE)’s Lawrence Berkeley National Laboratory (Berkeley Lab).
Historically, fly and human Polycomb proteins were considered textbook exemplars of transcriptional repressors, or proteins that silence the process by which DNA gives rise to new proteins.
Scientists at Cold Spring Harbor Laboratory have identified a candidate drug target for treating acute myeloid leukemia (AML), a white blood cell cancer that proliferates out of control in the bone marrow.
Cancer is usually attributed to faulty genes, but growing evidence from the field of cancer epigenetics indicates a key role for the gene “silencing” proteins that stably turn genes off inside the cell nucleus.
A new study published in the journal Nature Medicine by NYU Cancer Institute researchers, shows how the cancer causing gene Notch, in combination with a mutated Polycomb Repressive Complex 2 (PRC2) protein complex, work together to cause T- cell acute lymphoblastic leukemia (T-ALL).
The mechanism by which 'polycomb' proteins critical for embyronic stem cell function and fate are targeted to DNA has been identified by UCL scientists.
During embryonic development, proteins called Polycomb group complexes turn genes off when and where their activity must not be present, preventing specialized tissues and organs from forming in the wrong places.
New on-off switches: SUMO protein silences developmental genes, SNP2 snips SUMO to allow gene expression